Mr James Paul

  • Senior Research Fellow (Clinical Trials Research)

Research interests

I am Head of Biostatistics at the Cancer Research UK Clinical Trials Unit (CTU) based in the Beatson West of Scotland Cancer Center. The CTU is accredited by the National Cancer Research Institute and also by the UK Clinical Research Network. Jointly with the ISD Trials Office in Edinburgh we form the virtual organization, Cancer Clinical Trials Unit Scotland (CaCTUS).

The CTU supports clinical trials of all phases across a variety of different tumour types. We have a particularly strong relationship with the Scottish Gynaecological Trials Group and have worked with them over many years on a portfolio of trials, mainly in ovarian cancer. This has resulted in two large international phase III studies co-ordinated by the CTU: SCOTROC 1, published in 2003, which examined the question of the most approximate taxane (Docetaxel or Paclitaxel) to use and SCOTROC 4, currently recruiting, which is examining the question of the value of intra-patient dose escalation.

Currently the CTU is about to undertake a 9,500 patient randomised study in adjuvant colorectal cancer asking whether or not it is possible to halve treatment duration while maintaining the treatment effect. This study will also examine the issue of the best randomisation time-point in such a study (up-front to 12 or 24 weeks) or after 12 weeks (to stop or continue).

Personally I have a strong interest in translational work and have jointly supervised two PhD students working in this area looking at topics ranging from the best strategy for identifying prognostic factors to different approaches to analyzing data from genome wide DNA methylation microarrays.


Grants

Grants and Awards listed are those received whilst working with the University of Glasgow.

  • post extensions for 168650-01 CTU staff
    NHS Greater Glasgow and Clyde
    2018 - 2019
     
  • Precision-Panc: a dynamic therapeutic development platform for pancreatic cancer
    Cancer Research UK
    2017 - 2019
     
  • A Phase Ib/IIa clinical trial of FAK inhibitor VS6063 in combination with anti-PD1/PDL1 therapy
    Cancer Research UK
    2016 - 2020
     
  • ATLANTIS - Maintaining response in Urothelial Cancer: A Personalised Medicine Trial
    Cancer Research UK
    2016 - 2017
     
  • Extension of Follow-Up for High Risk Stage II Patients (additional 3 years) and Stage III Patients (up to year 3 follow-up) in the SCOT study.
    National Institute for Health Research
    2015 - 2018
     
  • Combined Suppression of cholesterol bioavailability and androgen de novo syntheseis to treat castrate resistant prostate cancer
    Prostate Cancer UK
    2015 - 2019
     
  • A clinical research fellowship in cancer clinical trials
    Cancer Research UK
    2015 - 2017
     
  • A Phase I study of Olaparib in Combination with Chemo-Radiation in Locally Advanced Pancreatic Cancer.
    Cancer Research UK
    2014 - 2020
     
  • An examination of diagnostic and prognostic biomarkers in malignant pleural mesothelioma
    Chief Scientist Office
    2013 - 2018
     
  • Cancer Research UK Clinical Trials Unit - Core Programme Funding
    Cancer Research UK
    2013 - 2018
     
  • BALLAD - A global study to evaluate the potential benefit of adjuvant chemotherapy for small bowel adenocarcinoma.
    Cancer Research UK
    2013 - 2018
     
  • Cancer and Venous Access (CAVA) - a three way randomised controlled trial of long-term venous access devices for the delivery of chemotherapy.
    National Institute for Health Research
    2013 - 2018
     
  • BriTROC - The UK Ovarian Cancer Translational Collaborative
    Ovarian Cancer Action
    2013 - 2018
     
  • MAdCaP: Mdm2 inhibition and Abiraterone in Carcinoma of the Prostate - a randomized phase II trial of abiraterone acetate with or without RO5045337
    Cancer Research UK
    2012 - 2016
     
  • TRANS PARAGON - Translational research in potentially hormone responsive recurrent/metastic gynaecological neoplasms.
    Cancer Research UK
    2012 - 2017
     
  • CROP Imaging substudy to the main trial (A randomised controlled trial of deferred androgen deprivation therapy +/- upfront cryotherapy in men with localised radiation recurrent prostate cancer.
    Cancer Research UK
    2012 - 2013
     
  • A Phase III randomised trial of Gemcitabine plus Docetaxel followed by Doxorubicin vs Observation for uterus-limited, high grade uterine leiomyosarcoma.
    Cancer Research UK
    2012 - 2015
     
  • tranSCOT - sample collection for translational studies in colorectal cancer.
    Cancer Research UK
    2012 - 2016
     
  • Phase I/IIA Study of AZD4547 in Combination with Cisplatin and Capecitabine (CX)
    Cancer Research UK
    2011 - 2017
     
  • A randomised controlled trial of deferred androgen deprivation therapy +/- upfront cryotherapy in men with localised radiation recurrent prostate cancer (RRPC) to evaluate efficacy and tolerability
    Cancer Research UK
    2011 - 2013
     
  • PARAGON - Phase II study of aromatase inhibitors in women with potentially hormone response recurrent/metastatic gynaecological neoplasms
    Cancer Research UK
    2011 - 2017
     
  • Understanding the development of persistent insomnia in breast cancer patients
    Breast Cancer Now
    2010 - 2013
     
  • A Randomised Doubleblind Phase II trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metaxtic/recurrant cervial cancer. (CIRCCA.)
    Cancer Research UK
    2010 - 2012
     
  • Experimental Cancer Medicine Centre (ECMC)
    Cancer Research UK
    2010 - 2012
     
  • A randomised Phase II trial of Imatinib (IM) versus hydroxychloroquine (HCQ) with IM for patients with chronic myeloid leukaemia (CML) in cytogenic response (CyR.
    Medical Research Council
    2010 - 2014
     
  • (CCCP-1) Randomised phase III of Paclitaxel plus Carboplatin therapy versus Irinotecan plus Cisplatin therapy as first line Chemotherapy for Clear Cell Carcinoma of the Ovary
    Cancer Research UK
    2010 - 2011
     
  • KPS (Ketamine Pain Study): A randomised double-blind controlled trial of S-Ketamine versus placebo in conjunction with best pain management in neuropathic pain in cancer patients
    Cancer Research UK
    2010 - 2013
     
  • CRUK Clinical Trials Unit Glasgow - Quinquennial review
    Cancer Research UK
    2009 - 2013
     
  • The CUP-ONE trial - a multi-centre randomised phase II study comparing epirubcin, cisplatin and capecitabine with and without Erlotinib in c
    Cancer Research UK
    2009 - 2014
     
  • SCOT - short course oncology therapy - a study of adjuvant chemotherapy in colorectal cancer by the CACTUS & QUASAR 3 groups
    Medical Research Council
    2007 - 2015
     
  • Provision of Statistical advice and support and to register and randomise patients into CRUK Protocol PH2/051
    Cancer Research UK
    2006 - 2009
     
  • SCOTROC 4 - A prospective multicentre randomised trial of carboplatin flat dosing vs intrapatient dose escalation......
    Scottish Gynaecological Cancer
    2006 - 2011
     
  • Randomised controlled clinical effectiveness trial of cognitive behaviour therapy versus treatment as usual for insomnia in cancer patients
    NHS Grampian
    2005 - 2005
     
  • Epigenetic Biomarkers for Ovarian Cancer Progression
    National Institute of Health
    2004 - 2006
     
  • Gynaecological cancer trials - Clinical Research Fellow
    Scottish Gynaecological Cancer
    2004 - 2007
     
  • Randomised controlled clinical effectiveness trial of cognitive behaviour therapy versus treatment as usual for insomnia in cancer patients
    Cancer Research UK
    2003 - 2006
     

Publications

List by: Type | Date

Jump to: 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001
Number of items: 118.

2018

Fleming, L., Randell, K., Stewart, E., Espie, C. A., Morrison, D. S., Lawless, C. and Paul, J. (2018) Insomnia in breast cancer: a prospective observational study. Sleep, (doi:10.1093/sleep/zsy245) (PMID:30521041) (Early Online Publication)

Robles-Zurita, J. A. et al. (2018) SCOT: A comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer. British Journal of Cancer, (doi:10.1038/s41416-018-0319-z) (Early Online Publication)

Stronach, E. A. et al. (2018) Biomarker assessment of HR deficiency, tumor BRCA1/2 mutations and CCNE1 copy number in ovarian cancer: associations with clinical outcome following platinum monotherapy. Molecular Cancer Research, 16(7), pp. 1103-1111. (doi:10.1158/1541-7786.MCR-18-0034) (PMID:29724815)

Fallon, M. T., Wilcock, A., Kelly, C. A., Paul, J. , Lewsley, L.-A., Norrie, J. and Laird, B. J.A. (2018) Oral ketamine vs placebo in patients with cancer-related neuropathic pain: a randomized clinical trial. JAMA Oncology, 4(6), pp. 870-872. (doi:10.1001/jamaoncol.2018.0131) (PMID:29621378) (PMCID:PMC6145686)

Ryan, C., Hesselgreaves, H., Wu, O. , Paul, J. , Dixon-Hughes, J. and Moss, J. G. (2018) Protocol for a systematic review and thematic synthesis of patient experiences of central venous access devices in anti-cancer treatment. Systematic Reviews, 7, 61. (doi:10.1186/s13643-018-0721-x) (PMID:29669583)

Dixon-Suen, S. C. et al. (2018) Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. British Journal of Cancer, 118(8), pp. 1123-1129. (doi:10.1038/s41416-018-0011-3) (PMID:29555990)

Iveson, T. J. et al. (2018) 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. Lancet Oncology, 19(4), pp. 562-578. (doi:10.1016/S1470-2045(18)30093-7) (PMID:29611518) (PMCID:PMC5883334)

Grothey, A. et al. (2018) Duration of adjuvant chemotherapy for stage III colon cancer. New England Journal of Medicine, 378(13), pp. 1177-1188. (doi:10.1056/NEJMoa1713709) (PMID:29590544)

Bilsland, A., Kelly, C., Roccisana, J., Paul, J. , Jones, R. , Edwards, J. , Roseweir, A. , Stein, T. and West, K. (2018) An Exploratory Study on the Use of Game-based Learning Using Microsoft Kinect to Teach Oncology Phase I Clinical Trial Designs. 2018 NCRI Cancer Conference, Glasgow, UK, 04-06 Nov 2018. (doi:10.1038/s41416-018-0299-z)

2017

Cooke, S. L. et al. (2017) The driver mutational landscape of ovarian squamous cell carcinomas arising in mature cystic teratoma. Clinical Cancer Research, 23(24), pp. 7633-7640. (doi:10.1158/1078-0432.CCR-17-1789) (PMID:28954785)

Paul, J. , Kelly, C., Stobo, J. and Powles, T. (2017) Reply to M. Horiguchi et al. Journal of Clinical Oncology, 35(29), pp. 3373-3374. (doi:10.1200/jco.2017.74.4292) (PMID:28800270)

Dicks, E. et al. (2017) Germline whole exome sequencing and large-scale replication identifies FANCM as a likely high grade serous ovarian cancer susceptibility gene. Oncotarget, 8(31), pp. 50930-50940. (doi:10.18632/oncotarget.15871) (PMID:28404948)

Jones, R. J. et al. (2017) Randomized phase II study investigating pazopanib versus weekly paclitaxel in relapsed or progressive urothelial cancer. Journal of Clinical Oncology, 35(16), pp. 1770-1777. (doi:10.1200/JCO.2016.70.7828) (PMID:28402747)

Flanagan, J. M. et al. (2017) Platinum-based chemotherapy induces methylation changes in blood DNA associated with overall survival in patients with ovarian cancer. Clinical Cancer Research, 23(9), pp. 2213-2222. (doi:10.1158/1078-0432.CCR-16-1754) (PMID:27663594)

Goranova, T. et al. (2017) Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma—experience of the BriTROC consortium. British Journal of Cancer, 116, pp. 1294-1301. (doi:10.1038/bjc.2017.86) (PMID:28359078)

Iveson, T. et al. (2017) Final DFS Results of the SCOT study: An International Phase III Randomised (1:1) Non-Inferiority Trial Comparing 3 Versus 6 Months of Oxaliplatin Based Adjuvant Chemotherapy for Colorectal Cancer. 42nd ESMO 2017 Congress, Madrid, Spain, 8-12 Sept 2017.

Phelan, C. M. et al. (2017) Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 49, pp. 680-691. (doi:10.1038/ng.3826) (PMID:28346442)

Sucheston-Campbell, L. E. et al. (2017) No evidence that genetic variation in the myeloid-derived suppressor cell pathway influences ovarian cancer survival. Cancer Epidemiology, Biomarkers and Prevention, 26(3), pp. 420-424. (doi:10.1158/1055-9965.EPI-16-0631) (PMID:27677730)

Kar, S. P. et al. (2017) Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. British Journal of Cancer, 116(4), pp. 524-535. (doi:10.1038/bjc.2016.426) (PMID:28103614)

Lawless, C.A. et al. (2017) ADSCaN: a randomised phase II study of accelerated, dose escalated, sequential chemo-radiotherapy in non-small cell lung cancer (NSCLC). UNSPECIFIED S80-S81. (doi:10.1016/S0169-5002(17)30221-0)

2016

Southey, M. C. et al. (2016) PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. Journal of Medical Genetics, 53(12), pp. 800-811. (doi:10.1136/jmedgenet-2016-103839) (PMID:27595995) (PMCID:PMC5200636)

Tsim, S. et al. (2016) Diagnostic and prognostic biomarkers in the rational assessment of mesothelioma (DIAPHRAGM) study: protocol of a prospective, multi-centre, observational study. BMJ Open, 6(11), e013324. (doi:10.1136/bmjopen-2016-013324) (PMID:27884852) (PMCID:PMC5168514)

Dixon, S. C. et al. (2016) Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. International Journal of Epidemiology, 45(3), pp. 884-895. (doi:10.1093/ije/dyw158) (PMID:27401727) (PMCID:PMC5644573)

He, Y.J., Winham, S.J., Hoskins, J.M., Glass, S., Paul, J. , Brown, R., Motsinger-Reif, A. and McLeod, H.L. (2016) Carboplatin/taxane-induced gastrointestinal toxicity: a pharmacogenomics study on the SCOTROC1 trial. Pharmacogenomics Journal, 16(3), pp. 243-248. (doi:10.1038/tpj.2015.52) (PMID:26194361)

Wu, O. , Boyd, K. , Paul, J. , McCartney, E. , Ritchie, M., Mellon, D., Kelly, L., Dixon-Hughes, J. and Moss, J. (2016) Hickman catheter and implantable port devices for the delivery of chemotherapy: a phase II randomised controlled trial and economic evaluation. British Journal of Cancer, 114(9), pp. 979-985. (doi:10.1038/bjc.2016.76) (PMID:27092784)

Hatton, M. Q. F., Hill, R., Fenwick, J. D., Morgan, S. A., Wilson, P. C., Atherton, P. J., Dickson, J., Murray, K. E. and Paul, J. (2016) Continuous hyperfractionated accelerated radiotherapy – escalated dose (CHART-ED): a phase I study. Radiotherapy and Oncology, 118(3), pp. 471-477. (doi:10.1016/j.radonc.2015.11.015) (PMID:26687902)

Hampras, S. S. et al. (2016) Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. Oncotarget, 7(43), pp. 69097-69110. (doi:10.18632/oncotarget.10215) (PMID:27533245)

2015

Johnatty, S. E. et al. (2015) Genome-wide analysis identifies novel loci associated with ovarian cancer outcomes: findings from the Ovarian Cancer Association Consortium. Clinical Cancer Research, 21(23), pp. 5264-5276. (doi:10.1158/1078-0432.CCR-15-0632) (PMID:26152742) (PMCID:PMC4624261)

Symonds, R. P. et al. (2015) Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncology, 16(15), pp. 1515-1524. (doi:10.1016/S1470-2045(15)00220-X) (PMID:26474517) (PMCID:PMC4705431)

Boyd, K. A. , Jones, R. J. , Paul, J. , Birrell, F., Briggs, A. H. and Leung, H. Y. (2015) Decision-analytic cost-effectiveness model to compare prostate cryotherapy to androgen deprivation therapy for treatment of radiation recurrent prostate cancer. BMJ Open, 5(10), e007925. (doi:10.1136/bmjopen-2015-007925) (PMID:26482768) (PMCID:PMC4611206)

Kar, S. P. et al. (2015) Network-based integration of GWAS and gene expression identifies a HOX-centric network associated with serous ovarian cancer risk. Cancer Epidemiology, Biomarkers and Prevention, 24(10), pp. 1574-1584. (doi:10.1158/1055-9965.epi-14-1270) (PMID:26209509)

Ritchie, M., Kelly, L., Moss, J., Paul, J. and Shaw, R. (2015) Exploring attitudes towards a randomised controlled trial of venous access devices – a nested pre-trial qualitative study. Journal of Vascular Access, 16(5), pp. 407-412. (doi:10.5301/jva.5000447) (PMID:26349872)

Lee, A. W. et al. (2015) Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study. Gynecologic Oncology, 136(3), pp. 542-548. (doi:10.1016/j.ygyno.2014.12.017) (PMID:25528498)

Bogaerts, J. et al. (2015) Clinical trial designs for rare diseases: studies developed and discussed by the international rare cancers initiative. European Journal of Cancer, 51(3), pp. 271-281. (doi:10.1016/j.ejca.2014.10.027) (PMID:25542058)

Chornokur, G. et al. (2015) Common genetic variation in cellular transport genes and epithelial ovarian cancer (EOC) risk. PLoS ONE, 10(6), e0128106. (doi:10.1371/journal.pone.0128106) (PMID:26091520) (PMCID:PMC4474865)

Kelemen, L.E. et al. (2015) Genome-wide significant risk associations for mucinous ovarian carcinoma. Nature Genetics, 47(8), pp. 888-897. (doi:10.1038/ng.3336) (PMID:26075790)

Kuchenbaecker, K. B. et al. (2015) Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 47(2), pp. 164-171. (doi:10.1038/ng.3185)

2014

Kelemen, L. E. et al. (2014) Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. Molecular Nutrition and Food Research, 58(10), pp. 2023-2035. (doi:10.1002/mnfr.201400068) (PMID:25066213)

Roxburgh, P. , Lumsden, G. R., Paul, J. , Harden, S., Sweeting, L., James, A., Crellin, A., Morrison, R., Evans, T. R. J. and McDonald, A. C. (2014) A phase I and pharmacokinetic study of capecitabine in combination with radiotherapy in patients with localised inoperable pancreatic cancer. Cancer Chemotherapy and Pharmacology, 74(1), pp. 131-139. (doi:10.1007/s00280-014-2470-4) (PMID:24819683)

Teo, M., Clark, B., MacKinnon, M., Stewart, W. , Paul, J. and St George, J. (2014) The validity of EORTC GBM prognostic calculator on survival of GBM patients in the West of Scotland. British Journal of Neurosurgery, 28(3), pp. 356-362. (doi:10.3109/02688697.2013.847171) (PMID:24111707)

Teo, M., Martin, S., Owusu-Agyemang, K., Nowicki, S., Clark, B., Mackinnon, M., Stewart, W. , Paul, J. and St George, J. (2014) A survival analysis of GBM patients in the West of Scotland pre- and post-introduction of the Stupp regime. British Journal of Neurosurgery, 28(3), pp. 351-355. (doi:10.3109/02688697.2013.847170) (PMID:24111708)

Boyd, K.A. , Jones, R.J. , Paul, J. , Briggs, A. and Leung, H.Y. (2014) A decision-analytic cost-effectiveness model to compare treatment options for radiation recurrent prostate cancer against androgen deprivation therapy. British Journal of Surgery, 101(s4), p. 59. (doi:10.1002/bjs.9510)

Earp, M. A. et al. (2014) Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. Human Genetics, 133(5), pp. 481-497. (doi:10.1007/s00439-013-1383-3)

Charbonneau, B. et al. (2014) Risk of ovarian cancer and the NF- B pathway: genetic association with IL1A and TNFSF10. Cancer Research, 74(3), pp. 852-861. (doi:10.1158/0008-5472.CAN-13-1051)

Paul, J. (2014) Targeted survival improvements in clinical trials: are you an absolutist or relativist? Cancer, 121(3), pp. 335-338. (doi:10.1002/cncr.29031) (PMID:25278175) (PMCID:4328455)

Glasspool, R.M. et al. (2014) A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer. British Journal of Cancer, 110(8), pp. 1923-1929. (doi:10.1038/bjc.2014.116)

Salji, M., Jones, R. , Paul, J. , Birrell, F., Dixon-Hughes, J., Hutchison, C., Johansen, T.E.B., Greene, D., Parr, N. and Leung, H.Y. (2014) Feasibility study of a randomised controlled trial to compare (deferred) androgen deprivation therapy and cryotherapy in men with localised radiation-recurrent prostate cancer. British Journal of Cancer, 111(3), pp. 424-429. (doi:10.1038/bjc.2014.316)

2013

Gallipoli, P. et al. (2013) Safety and efficacy of pulsed imatinib with or without G-CSFversuscontinuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up. British Journal of Haematology, 163(5), pp. 674-676. (doi:10.1111/bjh.12532)

Dai, W., Zeller, C., Masrour, N., Siddiqui, N., Paul, J. and Brown, R. (2013) Promoter CpG island methylation of genes in key cancer pathways associates with clinical outcome in high-grade serous ovarian cancer. Clinical Cancer Research, 19(20), pp. 5788-5797. (doi:10.1158/1078-0432.CCR-13-1217)

McWhinney-Glass, S., Winham, S.J., Hertz, D.L., Yen Revollo, J., Paul, J. , He, Y., Brown, R., Motsinger-Reif, A.A. and McLeod, H.L. (2013) Cumulative genetic risk predicts platinum/taxane-induced neurotoxicity. Clinical Cancer Research, 19(20), pp. 5769-5776. (doi:10.1158/1078-0432.CCR-13-0774)

Johnatty, S. E. et al. (2013) ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: A comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. Gynecologic Oncology, 131(1), pp. 8-14. (doi:10.1016/j.ygyno.2013.07.107)

Mitchell, A. J., Ferguson, D. W., Gill, J., Paul, J. and Symonds, P. (2013) Depression and anxiety in long-term cancer survivors compared with spouses and healthy controls: a systematic review and meta-analysis. Lancet Oncology, 14(8), pp. 721-732. (doi:10.1016/S1470-2045(13)70244-4)

White, K. L. et al. (2013) Analysis of over 10,000 cases finds no association between previously reported candidate polymorphisms and ovarian cancer outcome. Cancer Epidemiology, Biomarkers and Prevention, 22(5), pp. 987-992. (doi:10.1158/1055-9965.EPI-13-0028)

Bojesen, S. E. et al. (2013) Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 45(4), pp. 371-384. (doi:10.1038/ng.2566)

Chen, M. et al. (2013) Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex. Journal of the National Cancer Institute, 105(6), pp. 405-423. (doi:10.1093/jnci/djt006)

Doyle, B. et al. (2013) Raf kinase inhibitor protein expression combined with peritoneal involvement and lymphovascular invasion predicts prognosis in Dukes' B colorectal cancer patients. Histopathology, 62(3), pp. 505-510. (doi:10.1111/his.12014)

Banerjee, S. et al. (2013) A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG. Annals of Oncology, 24(3), pp. 679-687. (doi:10.1093/annonc/mds494)

Permuth-Wey, J. et al. (2013) Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nature Communications, 4(1627), (doi:10.1038/ncomms2613)

2012

Lindsay, R., Paul, J. , Siddiqui, N., Davis, J. and Gaffney, D. F. (2012) Survey on the management of early cervical cancer among members of the GCIG. International Journal of Gynecological Cancer, 22(9), pp. 1617-1623. (doi:10.1097/IGC.0b013e31826fd66b)

Cowan, C.C., Hutchison, C., Cole, T., Barry, S.J.E. , Paul, J. , Reed, N.S. and Russell, J.M. (2012) A randomised double-blind placebo-controlled trial to determine the effect of cranberry juice on decreasing the incidence of urinary symptoms and urinary tract infections in patients undergoing radiotherapy for cancer of the bladder or cervix. Clinical Oncology, 24(2), e31-e38. (doi:10.1016/j.clon.2011.05.009)

Doyle, B. et al. (2012) Raf kinase inhibitor protein (RKIP), lympho-vascular invasion and peritoneal invasion can be used to identify a high-risk group of stage II colorectal cancer patients. Modern Pathology, 25(S2), 159A. (doi:10.1038/modpathol.2012.17)

2011

Paul, J. , Iveson, T., Midgely, R., Harkin, A., Masterton, M., Alexander, L. and Cassidy, J. (2011) Choice of randomisation time-point in non-inferiority studies of reduced treatment duration: experience from the SCOT study. Trials, 12(Sup.1), A30. (doi:10.1186/1745-6215-12-S1-A30)

Huang, R.S. et al. (2011) Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clinical Cancer Research, 17(16), pp. 5490-5500. (doi:10.1158/1078-0432.CCR-11-0724)

Dai, W. et al. (2011) Systematic CpG islands methylation profiling of genes in the wnt pathway in epithelial ovarian cancer identifies biomarkers of progression-free survival. Clinical Cancer Research, 17(12), pp. 4052-4062. (doi:10.1158/1078-0432.CCR-10-3021)

He, Y., Wood, S.J., Paul, J. , Motsinger-Reif, A., Auman, T., Hoskins, J.M., Brown, R. and McLeod, H.L. (2011) Genetic markers associated with platinum/taxanes induced gastrointestinal toxicity in SCOTROC1 trial. Clinical Pharmacology and Therapeutics, 89, S4-S5. (doi:10.1038/clpt.2010.326)

Amankwah, E.K. et al. (2011) Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer: a report from the Ovarian Cancer Association Consortium. PLoS ONE, 6(5), e19642. (doi:10.1371/journal.pone.0019642)

Boyd, K.A. , Briggs, A. , Paul, J. , Iveson, T., Midgely, R., Harkin, A., Bates, G., Alexander, L. and Cassidy, J. (2011) Analysis of adverse events and quality of life data for an economic evaluation of adjuvant chemotherapy in colorectal cancer: when can we stop collecting? Trials, 12, A41. (doi:10.1186/1745-6215-12-S1-A41)

Pharoah, P.D.P. et al. (2011) The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clinical Cancer Research, 17(11), pp. 3742-3750. (doi:10.1158/1078-0432.CCR-10-3405)

Symonds, R.P., Davidson, S.E., Chan, S., Reed, N.S., McMahon, T., Rai, D., Harden, S. and Paul, J. (2011) SCOTCERV: A phase II trial of docetaxel and gemcitabine as second line chemotherapy in cervical cancer. Gynecologic Oncology, 123(1), pp. 105-109. (doi:10.1016/j.ygyno.2011.06.001)

2010

Bolton, K. L. et al. (2010) Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nature Genetics, 42(10), pp. 880-884. (doi:10.1038/ng.666)

Trimble, E.L. et al. (2010) Current academic clinical trials in ovarian cancer: gynecologic cancer intergroup and US national cancer institute clinical trials planning meeting, May 2009. International Journal of Gynecological Cancer, 20(7), pp. 1290-1298. (doi:10.1111/IGC.0b013e3181ee1c01)

Agarwal, R. et al. (2010) First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5): A feasibility study and comparative analysis of the SCOTROC series. European Journal of Cancer, 46(11), pp. 2020-2026. (doi:10.1016/j.ejca.2010.03.006)

Gourley, C. et al. (2010) Increased incidence of visceral metastases in Scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype. Journal of Clinical Oncology, 28(15), pp. 2505-2511. (doi:10.1200/JCO.2009.25.1082)

Paige, A.J.W. et al. (2010) WWOX tumour suppressor gene polymorphisms and ovarian cancer pathology and prognosis. European Journal of Cancer, 46(4), pp. 818-825. (doi:10.1016/j.ejca.2009.12.021)

2009

Scott, L., Evans, T. , Cassidy, J., Harden, S., Paul, J. , Ullah, R., O'Brien, V. and Brown, R. (2009) Cytokeratin 18 in plasma of patients with gastrointestinal adenocarcinoma as a biomarker of tumour response. British Journal of Cancer, 101(3), pp. 410-417. (doi:10.1038/sj.bjc.6605175)

Derakhshan, M.H., Liptrot, S., Paul, J. , Brown, I.L., Morrison, D.J. and McColl, K.E.L. (2009) Oesophageal and gastric intestinal-type adenocarcinomas show same male predominance - due to 17 year delayed development in females. Gut, 58(1), pp. 16-23. (doi:10.1136/gut.2008.161331)

Glasspool, R.M., Gore, M., Rustin, G., McNeish, I., Wilson, R., Pledge, S., Paul, J. , Mackean, M., Halford, S. and Kaye, S. (2009) Randomized phase II study of decitabine in combination with carboplatin compared with carboplatin alone in patients with recurrent advanced ovarian cancer. Journal of Clinical Oncology, 27(15), 5562. (doi:10.1200/jco.2009.27.15_suppl.5562) (PMID:27962569) (PMCID:27962569)

Kaye, S. B., Vasey, P., Rustin, G., Pledge, S., Williams, C., Gabra, H., Skailes, G., Lamont, A., Lewsley, L. and Paul, J. (2009) Randomized trial of intrapatient dose escalation of single agent carboplatin as first-line treatment for advanced ovarian cancer: An SGCTG study (SCOTROC 4). Journal of Clinical Oncology, 27(15), p. 5537.

2008

Johnatty, S.E. et al. (2008) ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy. Clinical Cancer Research, 14(17), pp. 5594-5601. (doi:10.1158/1078-0432.CCR-08-0606)

McLaren, V., Graham, J., Paul, J. and Dunlop, D. (2008) A phase II study of oxaliplatin and gemcitabine in advanced inoperable stage IIIB/IV non-small cell lung cancer. Journal of Clinical Oncology, 20(5), pp. 384-385. (doi:10.1016/j.clon.2008.03.007)

Vasey, P.A. et al. (2008) A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers. British Journal of Cancer, 98(11), pp. 1774-1780. (doi:10.1038/sj.bjc.6604371.)

Marsh, S., Paul, J. , McLeod, H.L. and Brown, R. (2008) Ethnic considerations in pharmacogenetic studies - In reply. Journal of Clinical Oncology, 26(10), pp. 1767-1768. (doi:10.1200/JCO.2007.15.8212)

Paul, J. , Marsh, S., McLeod, H.L. and Brown, R. (2008) No evidence for taxane/platinum pharmacogenetic markers: Just lack of power? Reply. Journal of Clinical Oncology, 26(11), pp. 1904-1905. (doi:10.1200/JCO.2007.15.9012)

Barrett, S.V., Paul, J. , Hay, A., Vasey, P.A., Kaye, S.B. and Glasspool, R.M. (2008) Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial. Annals of Oncology, 19(5), pp. 898-902. (doi:10.1093/annonc/mdm606)

Dai, W., Teodoridis, J.M., Graham, J., Zeller, C., Huang, T.H.M., Yan, P., Vass, J.K., Brown, R. and Paul, J. (2008) Methylation linear discriminant analysis (MLDA) for identifying differentially methylated CpG islands. BMC Bioinformatics, 9(337), (doi:10.1186/1471-2105-9-337)

Derakhshan, M.H., Liptrot, S., Paul, J. , Brown, I.L. and McColl, K.E.L. (2008) Male predominance of upper gastrointestinal cancer is related to intestinal histological subtype not tumour location. Gut, 57, A66-A67.

Espie, C., Fleming, L., Cassidy, J., Samuel, L., Taylor, L., White, C., Douglas, N., Engleman, H., Kelly, H. and Paul, J. (2008) Randomized controlled clinical effectiveness trial of cognitive behavior therapy compared with treatment as usual for persistent insomnia in patients with cancer. Journal of Clinical Oncology, 26(28), pp. 4651-4658. (doi:10.1200/JCO.2007.13.9006)

2007

Marsh, S., Paul, J. , King, C., Gifford, G., McLeod, H. and Brown, R. (2007) Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: The Scottish randomised trial in ovarian cancer. Journal of Clinical Oncology, 25(29), pp. 4528-4535. (doi:10.1200/JCO.2006.10.4752)

Hutchison, C., Cowan, C., McMahon, T. and Paul, J. (2007) A randomised controlled study of an audiovisual patient information intervention on informed consent and recruitment to cancer clinical trials. British Journal of Cancer, 97(6), pp. 705-711.

O'Rourke, N., Garcia, J., Paul, J. , Lawless, C., McMenemin, R. and Hill, J. (2007) A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma. Radiotherapy and Oncology, 84(1), pp. 18-22. (doi:10.1016/j.radonc.2007.05.022)

de Graeff, P. et al. (2007) The classification of p53 immunohistochemical staining results and patient outcome in ovarian cancer - Reply. British Journal of Cancer, 96(10), pp. 1623-1624. (doi:10.1038/sj.bjc.6603742)

Hutchison, C., Cowan, C. and Paul, J. (2007) Patient understanding of research: developing and testing of a new questionnaire. European Journal of Cancer Care, 16(2), pp. 187-196. (doi:10.1111/j.1365-2354.2006.00732.x)

2006

de Graeff, P. et al. (2006) Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies. British Journal of Cancer, 95(5), pp. 627-633. (doi:10.1038/sj.bjc.6603300)

Marsh, S., King, C., McLeod, H., Paul, J. , Gifford, G. and Brown, R. (2006) ABCB1 2677G > T/A genotype and paclitaxel pharmacogenetics in ovarian cancer. Clinical Cancer Research, 12(13), p. 4127. (doi:10.1158/1078-0432.CCR-06-0461)

Paul, J. , Briggs, A. , Harking, A., Hayclon, M., Iveson, T., Masterson, M., Midgley, A. and Cassidy, J. (2006) SCOT: short course oncology therapy — a comparison of 12 and 24 weeks of adjuvant chemotherapy in colorectal cancer. In: 2011 ASCO Annual Meeting, Chicago, Ill, USA, 3-7 Jun 2011, e14145.

Crawford, S., Paul, J. , Kaye, S., Vasey, P., Davis, J. and Hay, A. (2006) Aggressive surgery and ovarian cancer - Reply. Journal of Clinical Oncology, 24(15), pp. 2396-2397. (doi:10.1200/JCO.2006.05.8701)

Crawford, S., Paul, J. , Kaye, S., Vasey, P., Davis, J. and Hay, A. (2006) Importance of surgical aggressiveness in advanced ovarian cancer - Reply. Journal of Clinical Oncology, 24(15), pp. 2398-2399. (doi:10.1200/JCO.2006.06.3297)

Reed, N., Poole, C., Coleman, R., Parkin, D., Graham, J., Kaye, S., Ostrowski, J., Duncan, I., Paul, J. and Hay, A. (2006) A randomised comparison of treosulfan and carboplatin in patients with ovarian cancer: A study by the Scottish Gynaecological Cancer Trials Group (SGCTG). European Journal of Cancer, 42(2), pp. 179-185. (doi:10.1016/j.ejca.2005.09.022)

Vasey, P. et al. (2006) SCOTROC 2A: Carboplatin followed by docetaxel or docetaxel gemcitabine as first-line chemotherapy for ovarian cancer. British Journal of Cancer, 94(1), pp. 62-68. (doi:10.1038/sj.bjc.6602909)

2005

Crawford, S., Vasey, P., Paul, J. , Hay, A., Davis, J. and Kaye, S. (2005) Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial. Journal of Clinical Oncology, 23(34), pp. 8802-8811. (doi:10.1200/JCO.2005.02.1287)

Bruzzi, P., Del Mastro, L., Sormani, M., Bastholt, L., Danova, M., Focan, C., Fountzilas, G., Paul, J. , Rosso, R. and Venturini, M. (2005) Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients. Journal of Clinical Oncology, 23(22), pp. 5117-5125. (doi:10.1200/JCO.2005.02.106)

MacGregor, C., Canney, P., Patterson, G., McDonald, R. and Paul, J. (2005) A randomised double-blind controlled trial of oral soy supplements versus placebo for treatment of menopausal symptoms in patients with early breast cancer. European Journal of Cancer, 41(5), pp. 708-714. (doi:10.1016/j.ejca.2005.01.005)

2004

Vasey, P., Jayson, G., Gordon, A., Gabra, H., Coleman, R., Atkinson, R., Parkin, D., Paul, J. , Hay, A. and Kaye, S. (2004) Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. Journal of the National Cancer Institute, 96(22), pp. 1682-1691. (doi:10.1093/jnci/djh323)

Cook, G., Clark, R., Morris, T., Robertson, M., Lucie, N., Anderson, S., Paul, J. and Franklin, I. (2004) A randomized study (WOS MM1) comparing the oral regime Z-Dex (idarubicin and dexamethasone) with vincristine, adriamycin and clexamethasone as induction therapy for newly diagnosed patients with multiple myeloma. British Journal of Haematology, 126(6), pp. 792-798. (doi:10.1111/j.1365-2141.2004.05127.x)

Gifford, G., Paul, J. , Vasey, P., Kaye, S. and Brown, R. (2004) The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clinical Cancer Research, 10(13), pp. 4420-4426. (doi:10.1158/1078-0432.CCR-03-0732)

Anthoney, D., McKean, M., Roberts, J., Hutcheon, A., Graham, J., Jones, W., Paul, J. and Kaye, S. (2004) Bleomycin, vincristine, cisplatin/bleomycin, etoposide, cisplatin chemotherapy: an alternating, dose intense regimen producing promising results in untreated patients with intermediate or poor prognosis malignant germ-cell tumours. British Journal of Cancer, 90(3), pp. 601-606. (doi:10.1038/sj.bjc.6601528)

2003

Piccart, M. et al. (2003) Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. International Journal of Gynecological Cancer, 13(s2), pp. 144-148. (doi:10.1111/j.1525-1438.2003.13357.x)

Vasey, P., McMahon, L., Paul, J. , Reed, N. and Kaye, S. (2003) A phase II trial of capecitabine (Xeloda (R)) in recurrent ovarian cancer. British Journal of Cancer, 89(10), pp. 1843-1848. (doi:10.1038/sj.bjc.6601381)

Pentheroudakis, G. et al. (2003) Improved prognosis of patients with intermediate- and poor-risk nonseminomatous germ cell tumours by optimizing combined treatment. BJU International, 92(1), pp. 36-42. (doi:10.1046/j.1464-410X.2003.04261.x)

Kearney, N., Miller, M., Paul, J. , Smith, K. and Rice, A. (2003) Oncology health care professionals' attitudes to cancer: a professional concern. Annals of Oncology, 14(1), pp. 57-61. (doi:10.1093/annonc/mdg018)

Propper, D. et al. (2003) Use of positron emission tomography in pharmacokinetic studies to investigate therapeutic advantage in a phase I study of 120-hour intravenous infusion XR5000. Journal of Clinical Oncology, 21(2), pp. 203-210. (doi:10.1200/JCO.2003.02.008)

Flynn, P., Paul, J. and Cruickshank, D. (2003) Flynn et al.: does the interval from primary surgery to chemotherapy influence progression-free survival in ovarian cancer? - Reply. Gynecologic Oncology, 90(2), p. 498.

2002

Evans, T. , Pentheroudakis, G., Paul, J. , McInnes, A., Blackie, R., Raby, N., Morrison, R., Fullarton, G., Soukop, M. and McDonald, A. (2002) A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma. Annals of Oncology, 13(9), pp. 1469-1478. (doi:10.1093/annonc/mdf243)

Flynn, P.M., Paul, J. and Cruickshank, D.J. (2002) Does the Interval from Primary Surgery to Chemotherapy Influence Progression-Free Survival in Ovarian Cancer? Gynecologic Oncology, 86(3), pp. 354-357. (doi:10.1006/gyno.2002.6750)

O'Neill, V., Kaye, S., Reed, N., Paul, J. , Davis, J. and Vasey, P. (2002) A dose-finding study of carboplatin-epirubicin-docetaxel in advanced epithelial ovarian cancer. British Journal of Cancer, 86(9), pp. 1385-1390. (doi:10.1038/sj/bjc/6600259)

2001

Mackay, H. et al. (2001) A phase II study of epirubicin, cisplatin and raltitrexed combination chemotherapy (ECT) in patients with advanced oesophageal and gastric adenocarcinoma. Annals of Oncology, 12(10), pp. 1407-1410. (doi:10.1023/A:1012552823543)

Vasey, P. et al. (2001) Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer. British Journal of Cancer, 84(2), pp. 170-178. (doi:10.1054/bjoc.2000.1572)

Strathdee, G., Appleton, K., Illand, M., Millan, D., Sargent, J., Paul, J. and Brown, R. (2001) Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. American Journal of Pathology, 158, pp. 1121-1127. (doi:10.1016/S0002-9440(10)64059-X)

This list was generated on Sat Jan 19 19:33:54 2019 GMT.
Number of items: 118.

Articles

Fleming, L., Randell, K., Stewart, E., Espie, C. A., Morrison, D. S., Lawless, C. and Paul, J. (2018) Insomnia in breast cancer: a prospective observational study. Sleep, (doi:10.1093/sleep/zsy245) (PMID:30521041) (Early Online Publication)

Robles-Zurita, J. A. et al. (2018) SCOT: A comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer. British Journal of Cancer, (doi:10.1038/s41416-018-0319-z) (Early Online Publication)

Stronach, E. A. et al. (2018) Biomarker assessment of HR deficiency, tumor BRCA1/2 mutations and CCNE1 copy number in ovarian cancer: associations with clinical outcome following platinum monotherapy. Molecular Cancer Research, 16(7), pp. 1103-1111. (doi:10.1158/1541-7786.MCR-18-0034) (PMID:29724815)

Fallon, M. T., Wilcock, A., Kelly, C. A., Paul, J. , Lewsley, L.-A., Norrie, J. and Laird, B. J.A. (2018) Oral ketamine vs placebo in patients with cancer-related neuropathic pain: a randomized clinical trial. JAMA Oncology, 4(6), pp. 870-872. (doi:10.1001/jamaoncol.2018.0131) (PMID:29621378) (PMCID:PMC6145686)

Ryan, C., Hesselgreaves, H., Wu, O. , Paul, J. , Dixon-Hughes, J. and Moss, J. G. (2018) Protocol for a systematic review and thematic synthesis of patient experiences of central venous access devices in anti-cancer treatment. Systematic Reviews, 7, 61. (doi:10.1186/s13643-018-0721-x) (PMID:29669583)

Dixon-Suen, S. C. et al. (2018) Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. British Journal of Cancer, 118(8), pp. 1123-1129. (doi:10.1038/s41416-018-0011-3) (PMID:29555990)

Iveson, T. J. et al. (2018) 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. Lancet Oncology, 19(4), pp. 562-578. (doi:10.1016/S1470-2045(18)30093-7) (PMID:29611518) (PMCID:PMC5883334)

Grothey, A. et al. (2018) Duration of adjuvant chemotherapy for stage III colon cancer. New England Journal of Medicine, 378(13), pp. 1177-1188. (doi:10.1056/NEJMoa1713709) (PMID:29590544)

Cooke, S. L. et al. (2017) The driver mutational landscape of ovarian squamous cell carcinomas arising in mature cystic teratoma. Clinical Cancer Research, 23(24), pp. 7633-7640. (doi:10.1158/1078-0432.CCR-17-1789) (PMID:28954785)

Paul, J. , Kelly, C., Stobo, J. and Powles, T. (2017) Reply to M. Horiguchi et al. Journal of Clinical Oncology, 35(29), pp. 3373-3374. (doi:10.1200/jco.2017.74.4292) (PMID:28800270)

Dicks, E. et al. (2017) Germline whole exome sequencing and large-scale replication identifies FANCM as a likely high grade serous ovarian cancer susceptibility gene. Oncotarget, 8(31), pp. 50930-50940. (doi:10.18632/oncotarget.15871) (PMID:28404948)

Jones, R. J. et al. (2017) Randomized phase II study investigating pazopanib versus weekly paclitaxel in relapsed or progressive urothelial cancer. Journal of Clinical Oncology, 35(16), pp. 1770-1777. (doi:10.1200/JCO.2016.70.7828) (PMID:28402747)

Flanagan, J. M. et al. (2017) Platinum-based chemotherapy induces methylation changes in blood DNA associated with overall survival in patients with ovarian cancer. Clinical Cancer Research, 23(9), pp. 2213-2222. (doi:10.1158/1078-0432.CCR-16-1754) (PMID:27663594)

Goranova, T. et al. (2017) Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma—experience of the BriTROC consortium. British Journal of Cancer, 116, pp. 1294-1301. (doi:10.1038/bjc.2017.86) (PMID:28359078)

Phelan, C. M. et al. (2017) Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 49, pp. 680-691. (doi:10.1038/ng.3826) (PMID:28346442)

Sucheston-Campbell, L. E. et al. (2017) No evidence that genetic variation in the myeloid-derived suppressor cell pathway influences ovarian cancer survival. Cancer Epidemiology, Biomarkers and Prevention, 26(3), pp. 420-424. (doi:10.1158/1055-9965.EPI-16-0631) (PMID:27677730)

Kar, S. P. et al. (2017) Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. British Journal of Cancer, 116(4), pp. 524-535. (doi:10.1038/bjc.2016.426) (PMID:28103614)

Southey, M. C. et al. (2016) PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. Journal of Medical Genetics, 53(12), pp. 800-811. (doi:10.1136/jmedgenet-2016-103839) (PMID:27595995) (PMCID:PMC5200636)

Tsim, S. et al. (2016) Diagnostic and prognostic biomarkers in the rational assessment of mesothelioma (DIAPHRAGM) study: protocol of a prospective, multi-centre, observational study. BMJ Open, 6(11), e013324. (doi:10.1136/bmjopen-2016-013324) (PMID:27884852) (PMCID:PMC5168514)

Dixon, S. C. et al. (2016) Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. International Journal of Epidemiology, 45(3), pp. 884-895. (doi:10.1093/ije/dyw158) (PMID:27401727) (PMCID:PMC5644573)

He, Y.J., Winham, S.J., Hoskins, J.M., Glass, S., Paul, J. , Brown, R., Motsinger-Reif, A. and McLeod, H.L. (2016) Carboplatin/taxane-induced gastrointestinal toxicity: a pharmacogenomics study on the SCOTROC1 trial. Pharmacogenomics Journal, 16(3), pp. 243-248. (doi:10.1038/tpj.2015.52) (PMID:26194361)

Wu, O. , Boyd, K. , Paul, J. , McCartney, E. , Ritchie, M., Mellon, D., Kelly, L., Dixon-Hughes, J. and Moss, J. (2016) Hickman catheter and implantable port devices for the delivery of chemotherapy: a phase II randomised controlled trial and economic evaluation. British Journal of Cancer, 114(9), pp. 979-985. (doi:10.1038/bjc.2016.76) (PMID:27092784)

Hatton, M. Q. F., Hill, R., Fenwick, J. D., Morgan, S. A., Wilson, P. C., Atherton, P. J., Dickson, J., Murray, K. E. and Paul, J. (2016) Continuous hyperfractionated accelerated radiotherapy – escalated dose (CHART-ED): a phase I study. Radiotherapy and Oncology, 118(3), pp. 471-477. (doi:10.1016/j.radonc.2015.11.015) (PMID:26687902)

Hampras, S. S. et al. (2016) Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. Oncotarget, 7(43), pp. 69097-69110. (doi:10.18632/oncotarget.10215) (PMID:27533245)

Johnatty, S. E. et al. (2015) Genome-wide analysis identifies novel loci associated with ovarian cancer outcomes: findings from the Ovarian Cancer Association Consortium. Clinical Cancer Research, 21(23), pp. 5264-5276. (doi:10.1158/1078-0432.CCR-15-0632) (PMID:26152742) (PMCID:PMC4624261)

Symonds, R. P. et al. (2015) Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncology, 16(15), pp. 1515-1524. (doi:10.1016/S1470-2045(15)00220-X) (PMID:26474517) (PMCID:PMC4705431)

Boyd, K. A. , Jones, R. J. , Paul, J. , Birrell, F., Briggs, A. H. and Leung, H. Y. (2015) Decision-analytic cost-effectiveness model to compare prostate cryotherapy to androgen deprivation therapy for treatment of radiation recurrent prostate cancer. BMJ Open, 5(10), e007925. (doi:10.1136/bmjopen-2015-007925) (PMID:26482768) (PMCID:PMC4611206)

Kar, S. P. et al. (2015) Network-based integration of GWAS and gene expression identifies a HOX-centric network associated with serous ovarian cancer risk. Cancer Epidemiology, Biomarkers and Prevention, 24(10), pp. 1574-1584. (doi:10.1158/1055-9965.epi-14-1270) (PMID:26209509)

Ritchie, M., Kelly, L., Moss, J., Paul, J. and Shaw, R. (2015) Exploring attitudes towards a randomised controlled trial of venous access devices – a nested pre-trial qualitative study. Journal of Vascular Access, 16(5), pp. 407-412. (doi:10.5301/jva.5000447) (PMID:26349872)

Lee, A. W. et al. (2015) Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study. Gynecologic Oncology, 136(3), pp. 542-548. (doi:10.1016/j.ygyno.2014.12.017) (PMID:25528498)

Bogaerts, J. et al. (2015) Clinical trial designs for rare diseases: studies developed and discussed by the international rare cancers initiative. European Journal of Cancer, 51(3), pp. 271-281. (doi:10.1016/j.ejca.2014.10.027) (PMID:25542058)

Chornokur, G. et al. (2015) Common genetic variation in cellular transport genes and epithelial ovarian cancer (EOC) risk. PLoS ONE, 10(6), e0128106. (doi:10.1371/journal.pone.0128106) (PMID:26091520) (PMCID:PMC4474865)

Kelemen, L.E. et al. (2015) Genome-wide significant risk associations for mucinous ovarian carcinoma. Nature Genetics, 47(8), pp. 888-897. (doi:10.1038/ng.3336) (PMID:26075790)

Kuchenbaecker, K. B. et al. (2015) Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 47(2), pp. 164-171. (doi:10.1038/ng.3185)

Kelemen, L. E. et al. (2014) Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. Molecular Nutrition and Food Research, 58(10), pp. 2023-2035. (doi:10.1002/mnfr.201400068) (PMID:25066213)

Roxburgh, P. , Lumsden, G. R., Paul, J. , Harden, S., Sweeting, L., James, A., Crellin, A., Morrison, R., Evans, T. R. J. and McDonald, A. C. (2014) A phase I and pharmacokinetic study of capecitabine in combination with radiotherapy in patients with localised inoperable pancreatic cancer. Cancer Chemotherapy and Pharmacology, 74(1), pp. 131-139. (doi:10.1007/s00280-014-2470-4) (PMID:24819683)

Teo, M., Clark, B., MacKinnon, M., Stewart, W. , Paul, J. and St George, J. (2014) The validity of EORTC GBM prognostic calculator on survival of GBM patients in the West of Scotland. British Journal of Neurosurgery, 28(3), pp. 356-362. (doi:10.3109/02688697.2013.847171) (PMID:24111707)

Teo, M., Martin, S., Owusu-Agyemang, K., Nowicki, S., Clark, B., Mackinnon, M., Stewart, W. , Paul, J. and St George, J. (2014) A survival analysis of GBM patients in the West of Scotland pre- and post-introduction of the Stupp regime. British Journal of Neurosurgery, 28(3), pp. 351-355. (doi:10.3109/02688697.2013.847170) (PMID:24111708)

Boyd, K.A. , Jones, R.J. , Paul, J. , Briggs, A. and Leung, H.Y. (2014) A decision-analytic cost-effectiveness model to compare treatment options for radiation recurrent prostate cancer against androgen deprivation therapy. British Journal of Surgery, 101(s4), p. 59. (doi:10.1002/bjs.9510)

Earp, M. A. et al. (2014) Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. Human Genetics, 133(5), pp. 481-497. (doi:10.1007/s00439-013-1383-3)

Charbonneau, B. et al. (2014) Risk of ovarian cancer and the NF- B pathway: genetic association with IL1A and TNFSF10. Cancer Research, 74(3), pp. 852-861. (doi:10.1158/0008-5472.CAN-13-1051)

Paul, J. (2014) Targeted survival improvements in clinical trials: are you an absolutist or relativist? Cancer, 121(3), pp. 335-338. (doi:10.1002/cncr.29031) (PMID:25278175) (PMCID:4328455)

Glasspool, R.M. et al. (2014) A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer. British Journal of Cancer, 110(8), pp. 1923-1929. (doi:10.1038/bjc.2014.116)

Salji, M., Jones, R. , Paul, J. , Birrell, F., Dixon-Hughes, J., Hutchison, C., Johansen, T.E.B., Greene, D., Parr, N. and Leung, H.Y. (2014) Feasibility study of a randomised controlled trial to compare (deferred) androgen deprivation therapy and cryotherapy in men with localised radiation-recurrent prostate cancer. British Journal of Cancer, 111(3), pp. 424-429. (doi:10.1038/bjc.2014.316)

Gallipoli, P. et al. (2013) Safety and efficacy of pulsed imatinib with or without G-CSFversuscontinuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up. British Journal of Haematology, 163(5), pp. 674-676. (doi:10.1111/bjh.12532)

Dai, W., Zeller, C., Masrour, N., Siddiqui, N., Paul, J. and Brown, R. (2013) Promoter CpG island methylation of genes in key cancer pathways associates with clinical outcome in high-grade serous ovarian cancer. Clinical Cancer Research, 19(20), pp. 5788-5797. (doi:10.1158/1078-0432.CCR-13-1217)

McWhinney-Glass, S., Winham, S.J., Hertz, D.L., Yen Revollo, J., Paul, J. , He, Y., Brown, R., Motsinger-Reif, A.A. and McLeod, H.L. (2013) Cumulative genetic risk predicts platinum/taxane-induced neurotoxicity. Clinical Cancer Research, 19(20), pp. 5769-5776. (doi:10.1158/1078-0432.CCR-13-0774)

Johnatty, S. E. et al. (2013) ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: A comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. Gynecologic Oncology, 131(1), pp. 8-14. (doi:10.1016/j.ygyno.2013.07.107)

Mitchell, A. J., Ferguson, D. W., Gill, J., Paul, J. and Symonds, P. (2013) Depression and anxiety in long-term cancer survivors compared with spouses and healthy controls: a systematic review and meta-analysis. Lancet Oncology, 14(8), pp. 721-732. (doi:10.1016/S1470-2045(13)70244-4)

White, K. L. et al. (2013) Analysis of over 10,000 cases finds no association between previously reported candidate polymorphisms and ovarian cancer outcome. Cancer Epidemiology, Biomarkers and Prevention, 22(5), pp. 987-992. (doi:10.1158/1055-9965.EPI-13-0028)

Bojesen, S. E. et al. (2013) Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 45(4), pp. 371-384. (doi:10.1038/ng.2566)

Chen, M. et al. (2013) Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex. Journal of the National Cancer Institute, 105(6), pp. 405-423. (doi:10.1093/jnci/djt006)

Doyle, B. et al. (2013) Raf kinase inhibitor protein expression combined with peritoneal involvement and lymphovascular invasion predicts prognosis in Dukes' B colorectal cancer patients. Histopathology, 62(3), pp. 505-510. (doi:10.1111/his.12014)

Banerjee, S. et al. (2013) A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG. Annals of Oncology, 24(3), pp. 679-687. (doi:10.1093/annonc/mds494)

Permuth-Wey, J. et al. (2013) Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nature Communications, 4(1627), (doi:10.1038/ncomms2613)

Lindsay, R., Paul, J. , Siddiqui, N., Davis, J. and Gaffney, D. F. (2012) Survey on the management of early cervical cancer among members of the GCIG. International Journal of Gynecological Cancer, 22(9), pp. 1617-1623. (doi:10.1097/IGC.0b013e31826fd66b)

Cowan, C.C., Hutchison, C., Cole, T., Barry, S.J.E. , Paul, J. , Reed, N.S. and Russell, J.M. (2012) A randomised double-blind placebo-controlled trial to determine the effect of cranberry juice on decreasing the incidence of urinary symptoms and urinary tract infections in patients undergoing radiotherapy for cancer of the bladder or cervix. Clinical Oncology, 24(2), e31-e38. (doi:10.1016/j.clon.2011.05.009)

Doyle, B. et al. (2012) Raf kinase inhibitor protein (RKIP), lympho-vascular invasion and peritoneal invasion can be used to identify a high-risk group of stage II colorectal cancer patients. Modern Pathology, 25(S2), 159A. (doi:10.1038/modpathol.2012.17)

Paul, J. , Iveson, T., Midgely, R., Harkin, A., Masterton, M., Alexander, L. and Cassidy, J. (2011) Choice of randomisation time-point in non-inferiority studies of reduced treatment duration: experience from the SCOT study. Trials, 12(Sup.1), A30. (doi:10.1186/1745-6215-12-S1-A30)

Huang, R.S. et al. (2011) Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clinical Cancer Research, 17(16), pp. 5490-5500. (doi:10.1158/1078-0432.CCR-11-0724)

Dai, W. et al. (2011) Systematic CpG islands methylation profiling of genes in the wnt pathway in epithelial ovarian cancer identifies biomarkers of progression-free survival. Clinical Cancer Research, 17(12), pp. 4052-4062. (doi:10.1158/1078-0432.CCR-10-3021)

He, Y., Wood, S.J., Paul, J. , Motsinger-Reif, A., Auman, T., Hoskins, J.M., Brown, R. and McLeod, H.L. (2011) Genetic markers associated with platinum/taxanes induced gastrointestinal toxicity in SCOTROC1 trial. Clinical Pharmacology and Therapeutics, 89, S4-S5. (doi:10.1038/clpt.2010.326)

Amankwah, E.K. et al. (2011) Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer: a report from the Ovarian Cancer Association Consortium. PLoS ONE, 6(5), e19642. (doi:10.1371/journal.pone.0019642)

Boyd, K.A. , Briggs, A. , Paul, J. , Iveson, T., Midgely, R., Harkin, A., Bates, G., Alexander, L. and Cassidy, J. (2011) Analysis of adverse events and quality of life data for an economic evaluation of adjuvant chemotherapy in colorectal cancer: when can we stop collecting? Trials, 12, A41. (doi:10.1186/1745-6215-12-S1-A41)

Pharoah, P.D.P. et al. (2011) The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clinical Cancer Research, 17(11), pp. 3742-3750. (doi:10.1158/1078-0432.CCR-10-3405)

Symonds, R.P., Davidson, S.E., Chan, S., Reed, N.S., McMahon, T., Rai, D., Harden, S. and Paul, J. (2011) SCOTCERV: A phase II trial of docetaxel and gemcitabine as second line chemotherapy in cervical cancer. Gynecologic Oncology, 123(1), pp. 105-109. (doi:10.1016/j.ygyno.2011.06.001)

Bolton, K. L. et al. (2010) Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nature Genetics, 42(10), pp. 880-884. (doi:10.1038/ng.666)

Trimble, E.L. et al. (2010) Current academic clinical trials in ovarian cancer: gynecologic cancer intergroup and US national cancer institute clinical trials planning meeting, May 2009. International Journal of Gynecological Cancer, 20(7), pp. 1290-1298. (doi:10.1111/IGC.0b013e3181ee1c01)

Agarwal, R. et al. (2010) First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5): A feasibility study and comparative analysis of the SCOTROC series. European Journal of Cancer, 46(11), pp. 2020-2026. (doi:10.1016/j.ejca.2010.03.006)

Gourley, C. et al. (2010) Increased incidence of visceral metastases in Scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype. Journal of Clinical Oncology, 28(15), pp. 2505-2511. (doi:10.1200/JCO.2009.25.1082)

Paige, A.J.W. et al. (2010) WWOX tumour suppressor gene polymorphisms and ovarian cancer pathology and prognosis. European Journal of Cancer, 46(4), pp. 818-825. (doi:10.1016/j.ejca.2009.12.021)

Scott, L., Evans, T. , Cassidy, J., Harden, S., Paul, J. , Ullah, R., O'Brien, V. and Brown, R. (2009) Cytokeratin 18 in plasma of patients with gastrointestinal adenocarcinoma as a biomarker of tumour response. British Journal of Cancer, 101(3), pp. 410-417. (doi:10.1038/sj.bjc.6605175)

Derakhshan, M.H., Liptrot, S., Paul, J. , Brown, I.L., Morrison, D.J. and McColl, K.E.L. (2009) Oesophageal and gastric intestinal-type adenocarcinomas show same male predominance - due to 17 year delayed development in females. Gut, 58(1), pp. 16-23. (doi:10.1136/gut.2008.161331)

Glasspool, R.M., Gore, M., Rustin, G., McNeish, I., Wilson, R., Pledge, S., Paul, J. , Mackean, M., Halford, S. and Kaye, S. (2009) Randomized phase II study of decitabine in combination with carboplatin compared with carboplatin alone in patients with recurrent advanced ovarian cancer. Journal of Clinical Oncology, 27(15), 5562. (doi:10.1200/jco.2009.27.15_suppl.5562) (PMID:27962569) (PMCID:27962569)

Kaye, S. B., Vasey, P., Rustin, G., Pledge, S., Williams, C., Gabra, H., Skailes, G., Lamont, A., Lewsley, L. and Paul, J. (2009) Randomized trial of intrapatient dose escalation of single agent carboplatin as first-line treatment for advanced ovarian cancer: An SGCTG study (SCOTROC 4). Journal of Clinical Oncology, 27(15), p. 5537.

Johnatty, S.E. et al. (2008) ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy. Clinical Cancer Research, 14(17), pp. 5594-5601. (doi:10.1158/1078-0432.CCR-08-0606)

McLaren, V., Graham, J., Paul, J. and Dunlop, D. (2008) A phase II study of oxaliplatin and gemcitabine in advanced inoperable stage IIIB/IV non-small cell lung cancer. Journal of Clinical Oncology, 20(5), pp. 384-385. (doi:10.1016/j.clon.2008.03.007)

Vasey, P.A. et al. (2008) A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers. British Journal of Cancer, 98(11), pp. 1774-1780. (doi:10.1038/sj.bjc.6604371.)

Marsh, S., Paul, J. , McLeod, H.L. and Brown, R. (2008) Ethnic considerations in pharmacogenetic studies - In reply. Journal of Clinical Oncology, 26(10), pp. 1767-1768. (doi:10.1200/JCO.2007.15.8212)

Paul, J. , Marsh, S., McLeod, H.L. and Brown, R. (2008) No evidence for taxane/platinum pharmacogenetic markers: Just lack of power? Reply. Journal of Clinical Oncology, 26(11), pp. 1904-1905. (doi:10.1200/JCO.2007.15.9012)

Barrett, S.V., Paul, J. , Hay, A., Vasey, P.A., Kaye, S.B. and Glasspool, R.M. (2008) Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial. Annals of Oncology, 19(5), pp. 898-902. (doi:10.1093/annonc/mdm606)

Dai, W., Teodoridis, J.M., Graham, J., Zeller, C., Huang, T.H.M., Yan, P., Vass, J.K., Brown, R. and Paul, J. (2008) Methylation linear discriminant analysis (MLDA) for identifying differentially methylated CpG islands. BMC Bioinformatics, 9(337), (doi:10.1186/1471-2105-9-337)

Derakhshan, M.H., Liptrot, S., Paul, J. , Brown, I.L. and McColl, K.E.L. (2008) Male predominance of upper gastrointestinal cancer is related to intestinal histological subtype not tumour location. Gut, 57, A66-A67.

Espie, C., Fleming, L., Cassidy, J., Samuel, L., Taylor, L., White, C., Douglas, N., Engleman, H., Kelly, H. and Paul, J. (2008) Randomized controlled clinical effectiveness trial of cognitive behavior therapy compared with treatment as usual for persistent insomnia in patients with cancer. Journal of Clinical Oncology, 26(28), pp. 4651-4658. (doi:10.1200/JCO.2007.13.9006)

Marsh, S., Paul, J. , King, C., Gifford, G., McLeod, H. and Brown, R. (2007) Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: The Scottish randomised trial in ovarian cancer. Journal of Clinical Oncology, 25(29), pp. 4528-4535. (doi:10.1200/JCO.2006.10.4752)

Hutchison, C., Cowan, C., McMahon, T. and Paul, J. (2007) A randomised controlled study of an audiovisual patient information intervention on informed consent and recruitment to cancer clinical trials. British Journal of Cancer, 97(6), pp. 705-711.

O'Rourke, N., Garcia, J., Paul, J. , Lawless, C., McMenemin, R. and Hill, J. (2007) A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma. Radiotherapy and Oncology, 84(1), pp. 18-22. (doi:10.1016/j.radonc.2007.05.022)

de Graeff, P. et al. (2007) The classification of p53 immunohistochemical staining results and patient outcome in ovarian cancer - Reply. British Journal of Cancer, 96(10), pp. 1623-1624. (doi:10.1038/sj.bjc.6603742)

Hutchison, C., Cowan, C. and Paul, J. (2007) Patient understanding of research: developing and testing of a new questionnaire. European Journal of Cancer Care, 16(2), pp. 187-196. (doi:10.1111/j.1365-2354.2006.00732.x)

de Graeff, P. et al. (2006) Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies. British Journal of Cancer, 95(5), pp. 627-633. (doi:10.1038/sj.bjc.6603300)

Marsh, S., King, C., McLeod, H., Paul, J. , Gifford, G. and Brown, R. (2006) ABCB1 2677G > T/A genotype and paclitaxel pharmacogenetics in ovarian cancer. Clinical Cancer Research, 12(13), p. 4127. (doi:10.1158/1078-0432.CCR-06-0461)

Crawford, S., Paul, J. , Kaye, S., Vasey, P., Davis, J. and Hay, A. (2006) Aggressive surgery and ovarian cancer - Reply. Journal of Clinical Oncology, 24(15), pp. 2396-2397. (doi:10.1200/JCO.2006.05.8701)

Crawford, S., Paul, J. , Kaye, S., Vasey, P., Davis, J. and Hay, A. (2006) Importance of surgical aggressiveness in advanced ovarian cancer - Reply. Journal of Clinical Oncology, 24(15), pp. 2398-2399. (doi:10.1200/JCO.2006.06.3297)

Reed, N., Poole, C., Coleman, R., Parkin, D., Graham, J., Kaye, S., Ostrowski, J., Duncan, I., Paul, J. and Hay, A. (2006) A randomised comparison of treosulfan and carboplatin in patients with ovarian cancer: A study by the Scottish Gynaecological Cancer Trials Group (SGCTG). European Journal of Cancer, 42(2), pp. 179-185. (doi:10.1016/j.ejca.2005.09.022)

Vasey, P. et al. (2006) SCOTROC 2A: Carboplatin followed by docetaxel or docetaxel gemcitabine as first-line chemotherapy for ovarian cancer. British Journal of Cancer, 94(1), pp. 62-68. (doi:10.1038/sj.bjc.6602909)

Crawford, S., Vasey, P., Paul, J. , Hay, A., Davis, J. and Kaye, S. (2005) Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial. Journal of Clinical Oncology, 23(34), pp. 8802-8811. (doi:10.1200/JCO.2005.02.1287)

Bruzzi, P., Del Mastro, L., Sormani, M., Bastholt, L., Danova, M., Focan, C., Fountzilas, G., Paul, J. , Rosso, R. and Venturini, M. (2005) Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients. Journal of Clinical Oncology, 23(22), pp. 5117-5125. (doi:10.1200/JCO.2005.02.106)

MacGregor, C., Canney, P., Patterson, G., McDonald, R. and Paul, J. (2005) A randomised double-blind controlled trial of oral soy supplements versus placebo for treatment of menopausal symptoms in patients with early breast cancer. European Journal of Cancer, 41(5), pp. 708-714. (doi:10.1016/j.ejca.2005.01.005)

Vasey, P., Jayson, G., Gordon, A., Gabra, H., Coleman, R., Atkinson, R., Parkin, D., Paul, J. , Hay, A. and Kaye, S. (2004) Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. Journal of the National Cancer Institute, 96(22), pp. 1682-1691. (doi:10.1093/jnci/djh323)

Cook, G., Clark, R., Morris, T., Robertson, M., Lucie, N., Anderson, S., Paul, J. and Franklin, I. (2004) A randomized study (WOS MM1) comparing the oral regime Z-Dex (idarubicin and dexamethasone) with vincristine, adriamycin and clexamethasone as induction therapy for newly diagnosed patients with multiple myeloma. British Journal of Haematology, 126(6), pp. 792-798. (doi:10.1111/j.1365-2141.2004.05127.x)

Gifford, G., Paul, J. , Vasey, P., Kaye, S. and Brown, R. (2004) The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clinical Cancer Research, 10(13), pp. 4420-4426. (doi:10.1158/1078-0432.CCR-03-0732)

Anthoney, D., McKean, M., Roberts, J., Hutcheon, A., Graham, J., Jones, W., Paul, J. and Kaye, S. (2004) Bleomycin, vincristine, cisplatin/bleomycin, etoposide, cisplatin chemotherapy: an alternating, dose intense regimen producing promising results in untreated patients with intermediate or poor prognosis malignant germ-cell tumours. British Journal of Cancer, 90(3), pp. 601-606. (doi:10.1038/sj.bjc.6601528)

Piccart, M. et al. (2003) Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. International Journal of Gynecological Cancer, 13(s2), pp. 144-148. (doi:10.1111/j.1525-1438.2003.13357.x)

Vasey, P., McMahon, L., Paul, J. , Reed, N. and Kaye, S. (2003) A phase II trial of capecitabine (Xeloda (R)) in recurrent ovarian cancer. British Journal of Cancer, 89(10), pp. 1843-1848. (doi:10.1038/sj.bjc.6601381)

Pentheroudakis, G. et al. (2003) Improved prognosis of patients with intermediate- and poor-risk nonseminomatous germ cell tumours by optimizing combined treatment. BJU International, 92(1), pp. 36-42. (doi:10.1046/j.1464-410X.2003.04261.x)

Kearney, N., Miller, M., Paul, J. , Smith, K. and Rice, A. (2003) Oncology health care professionals' attitudes to cancer: a professional concern. Annals of Oncology, 14(1), pp. 57-61. (doi:10.1093/annonc/mdg018)

Propper, D. et al. (2003) Use of positron emission tomography in pharmacokinetic studies to investigate therapeutic advantage in a phase I study of 120-hour intravenous infusion XR5000. Journal of Clinical Oncology, 21(2), pp. 203-210. (doi:10.1200/JCO.2003.02.008)

Flynn, P., Paul, J. and Cruickshank, D. (2003) Flynn et al.: does the interval from primary surgery to chemotherapy influence progression-free survival in ovarian cancer? - Reply. Gynecologic Oncology, 90(2), p. 498.

Evans, T. , Pentheroudakis, G., Paul, J. , McInnes, A., Blackie, R., Raby, N., Morrison, R., Fullarton, G., Soukop, M. and McDonald, A. (2002) A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma. Annals of Oncology, 13(9), pp. 1469-1478. (doi:10.1093/annonc/mdf243)

Flynn, P.M., Paul, J. and Cruickshank, D.J. (2002) Does the Interval from Primary Surgery to Chemotherapy Influence Progression-Free Survival in Ovarian Cancer? Gynecologic Oncology, 86(3), pp. 354-357. (doi:10.1006/gyno.2002.6750)

O'Neill, V., Kaye, S., Reed, N., Paul, J. , Davis, J. and Vasey, P. (2002) A dose-finding study of carboplatin-epirubicin-docetaxel in advanced epithelial ovarian cancer. British Journal of Cancer, 86(9), pp. 1385-1390. (doi:10.1038/sj/bjc/6600259)

Mackay, H. et al. (2001) A phase II study of epirubicin, cisplatin and raltitrexed combination chemotherapy (ECT) in patients with advanced oesophageal and gastric adenocarcinoma. Annals of Oncology, 12(10), pp. 1407-1410. (doi:10.1023/A:1012552823543)

Vasey, P. et al. (2001) Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer. British Journal of Cancer, 84(2), pp. 170-178. (doi:10.1054/bjoc.2000.1572)

Strathdee, G., Appleton, K., Illand, M., Millan, D., Sargent, J., Paul, J. and Brown, R. (2001) Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. American Journal of Pathology, 158, pp. 1121-1127. (doi:10.1016/S0002-9440(10)64059-X)

Conference or Workshop Item

Bilsland, A., Kelly, C., Roccisana, J., Paul, J. , Jones, R. , Edwards, J. , Roseweir, A. , Stein, T. and West, K. (2018) An Exploratory Study on the Use of Game-based Learning Using Microsoft Kinect to Teach Oncology Phase I Clinical Trial Designs. 2018 NCRI Cancer Conference, Glasgow, UK, 04-06 Nov 2018. (doi:10.1038/s41416-018-0299-z)

Iveson, T. et al. (2017) Final DFS Results of the SCOT study: An International Phase III Randomised (1:1) Non-Inferiority Trial Comparing 3 Versus 6 Months of Oxaliplatin Based Adjuvant Chemotherapy for Colorectal Cancer. 42nd ESMO 2017 Congress, Madrid, Spain, 8-12 Sept 2017.

Lawless, C.A. et al. (2017) ADSCaN: a randomised phase II study of accelerated, dose escalated, sequential chemo-radiotherapy in non-small cell lung cancer (NSCLC). UNSPECIFIED S80-S81. (doi:10.1016/S0169-5002(17)30221-0)

Conference Proceedings

Paul, J. , Briggs, A. , Harking, A., Hayclon, M., Iveson, T., Masterson, M., Midgley, A. and Cassidy, J. (2006) SCOT: short course oncology therapy — a comparison of 12 and 24 weeks of adjuvant chemotherapy in colorectal cancer. In: 2011 ASCO Annual Meeting, Chicago, Ill, USA, 3-7 Jun 2011, e14145.

This list was generated on Sat Jan 19 19:33:54 2019 GMT.